Waters closes $17.5B BD acquisition as Q4 results meet expectations
Life sciences instrument maker doubles addressable market in transformative deal
Waters Corporation completed its $17.5 billion acquisition of BD's Biosciences & Diagnostic Solutions business on Monday, transforming the Massachusetts-based laboratory instrument maker into a life sciences and diagnostics powerhouse with a doubled addressable market.
The deal, structured as a tax-efficient Reverse Morris Trust, creates a combined company with pro forma revenue of approximately $6.5 billion for calendar year 2025. BD shareholders will own 39.2% of the merged entity, while existing Waters shareholders retain 60.8% ownership.
Waters shares rose 1.2% to $381.29 in Monday trading as investors digested the closing alongside fourth-quarter earnings that essentially met analyst expectations. The Milford, Massachusetts-based company reported adjusted earnings per share of $4.53, topping the Zacks consensus estimate of $4.50 by 3 cents, according to Zacks Investment Research. Revenue reached $932.4 million, exceeding Street forecasts of $927.3 million.
The acquisition represents a strategic pivot for Waters, which has historically focused on analytical instrumentation including liquid chromatography and mass spectrometry systems. By adding BD's flow cytometry and diagnostic solutions, the combined company will now span the entire laboratory workflow—from research and discovery to regulated high-volume testing.
"This combination creates a premier life science and diagnostics company focused on regulated, high-volume testing markets," Waters said in a statement. "The combined company will offer customers an expanded portfolio of liquid chromatography, mass spectrometry, flow cytometry, and diagnostic solutions."
The deal is expected to generate $200 million in cost synergies by the third year post-closing and $290 million in revenue synergies by year five, resulting in approximately $345 million of annualized EBITDA synergies by 2030. Waters' total addressable market will expand from roughly $20 billion to approximately $40 billion.
For fiscal 2026, Waters issued guidance largely in line with analyst expectations. The company projects earnings per share of $14.30 to $14.50, compared to the consensus estimate of $14.32. Revenue guidance of $3.36 billion to $3.41 billion matches the Street view of $3.37 billion. The outlook includes an approximate $3.0 billion revenue contribution from the BD Biosciences business.
The guidance projects organic constant currency revenue growth of 5.5% to 7.0% for the full year, suggesting the core business continues to grow steadily even as integration challenges loom.
Udit Batra, Waters' current chief executive officer, will lead the combined entity. Under the terms of the transaction, BD receives a $4 billion cash distribution prior to completion, while Waters assumes approximately $4 billion of incremental debt.
Analysts maintain a generally positive outlook on the stock despite integration risks. The average analyst target price stands at $416.94, representing approximately 9.3% upside from current levels, according to market data. Waters trades at a trailing price-to-earnings ratio of 35.1 and a forward multiple of 27.6, suggesting investors are pricing in successful execution of the integration strategy.
The fourth-quarter results marked the fourth consecutive quarter that Waters has beaten EPS estimates, albeit by modest margins. Reported revenue growth for the quarter reached 7%, with constant currency growth at 6%.
Investors will be watching closely for signs of integration progress when Waters holds its earnings conference call at 8:30 AM ET on Monday. The successful combination of two complex life sciences businesses with distinct cultures and product portfolios represents a significant challenge, even as the strategic rationale appears compelling.